Document:

THE SHARES OF COMMON STOCK SUBSCRIBED FOR BY THIS AGREEMENT HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY OTHER APPLICABLE
STATE SECURITIES LAWS AND TRANSFER OF SUCH SHARES IS RESTRICTED BY THE TERMS OF
THIS AGREEMENT.

                             SUBSCRIPTION AGREEMENT

      This SUBSCRIPTION AGREEMENT (the "Agreement") is made by and between the
subscriber hereto (the "Subscriber") and Calypte Biomedical Corporation, a
Delaware corporation (the "Company").

      The Subscriber hereby agrees to purchase, and the Company hereby agrees to
issue and to sell to the Subscriber, the number of shares (the "Shares") of
common stock of the Company, par value $.03 per share (the "Common Stock") set
forth on the signature page, for a purchase price in cash equal to $0.18 per
share (the aggregate amount to be paid by the Subscriber shall be referred to as
the "Purchase Price"). After acceptance of this agreement (the "Agreement") by
the Company and payment and delivery by the Subscriber to the Company of the
Purchase Price in the form of wire transfer pursuant to the terms of Section
7(b) of this Agreement, the Company shall issue and deliver to the Subscriber
the Shares.

      NOW, THEREFORE, in order to implement the foregoing and in consideration
of the mutual representations, warranties, covenants and agreements contained
herein and for other good and valuable consideration, the receipt and adequacy
of which are hereby acknowledged, the parties hereto agree as follows.

      1. Subscriber's Representations and Warranties. The Subscriber hereby
represents and warrants to and agrees with the Company that:

            (a) Information on Company. The Subscriber has been furnished with
the Company's Form 10-KSB for the year ended December 31, 2005 as filed with the
Securities and Exchange Commission (the "Commission") together with all
subsequently filed Forms 10-QSB, 8-K, Proxy Statement, and other publicly
available filings made with the Commission (hereinafter referred to collectively
as the "Reports"). In addition, the Subscriber has received from the Company
such other information concerning its operations, financial condition and other
matters as the Subscriber has requested (such information in writing is
collectively, the "Other Written Information"), and considered all factors the
Subscriber deems material in deciding on the advisability of purchasing the
Shares.

            (b) Information on Subscriber. The Subscriber is and was not a "U.S.
person," as defined in Regulation S of the Securities Act of 1933, as amended
(the "1933 Act"), at the time the offer or sale of the Shares is made.
Additionally, the Subscriber is an "accredited investor," as such term is
defined in Regulation D of the 1933 Act or is part of a group of companies that
is experienced in investments and business matters, has made investments of a
speculative nature and has purchased securities of United States publicly-owned
companies in private placements in the past and, with its representatives, has
such knowledge and experience in financial, tax and other business matters as to
enable the Subscriber to utilize the information made available by the Company
to evaluate the merits and risks of and to make an informed investment decision
with respect to the proposed purchase, which represents a speculative
investment. The Subscriber is a natural person or an entity duly organized,
validly existing and in good standing under the laws of the jurisdiction of its
organization with the requisite corporate or partnership power and authority to
enter into and to consummate the transactions contemplated by this Agreement and
otherwise to carry out its obligations hereunder. The execution, delivery and
performance by the Subscriber of the transactions contemplated by this Agreement
has been duly authorized by all necessary corporate or, if the Subscriber is not
a corporation, such partnership, limited liability company or other applicable
like action, on the part of the Subscriber. This Agreement has been duly
executed by the Subscriber and when delivered by the Subscriber in accordance
with terms hereof, will constitute the valid and legally binding obligation of
the Subscriber, enforceable against it in accordance with its terms, except as
such enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation or similar laws relating to, or
affecting generally the enforcement of, creditors' rights and remedies or by
other equitable principles of general application. The Subscriber is able to
bear the risk of such investment for an indefinite period and to afford a
complete loss thereof. The information set forth on the signature page hereto
regarding the Subscriber is accurate.

                                                                          Page 1
<PAGE>

            (c) Purchase of Shares and Investment Intent. On the Closing Date,
the Subscriber will purchase the Shares for its own account for the Purchase
Price. The Subscriber is acquiring the Shares as principal for its own account
for investment purposes only and not with a view to or for distributing or
reselling such Shares or any part thereof, without prejudice, however, to the
Subscriber's right at all times to sell or otherwise dispose of all or any part
of such Shares in compliance with applicable federal and state securities laws.
Subject to the immediately preceding sentence, nothing contained herein shall be
deemed a representation or warranty by such Investor to hold the Shares for any
period of time. Such Investor is acquiring the Shares hereunder in the ordinary
course of its business. Such Investor does not have any agreement or
understanding, directly or indirectly, with any person to distribute any of the
Shares. The Subscriber also represents that its purchase of the Shares is
intended to be made as an "Offshore Transaction" as defined in Regulation S.

            (d) Compliance with Securities Act. The Subscriber understands and
agrees that the Shares have not been registered under the 1933 Act, by reason of
their issuance in a transaction that does not require registration under the
1933 Act (based in part on the accuracy of the representations and warranties of
the Subscriber contained herein), and that such Shares must be held unless a
subsequent disposition is registered under the 1933 Act or is exempt from such
registration.

            (e) Legend on Shares. The Shares shall bear the following legend,
unless the Shares shall have been included in an effective registration
statement under the 1933 Act:

      "THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER
      THE SECURITIES ACT OF 1933, AS AMENDED. THESE SHARES MAY NOT BE SOLD,
      OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE
      REGISTRATION STATEMENT UNDER SUCH SECURITIES ACT OR AN OPINION OF COUNSEL
      REASONABLY SATISFACTORY TO CALYPTE BIOMEDICAL CORPORATION THAT SUCH
      REGISTRATION IS NOT REQUIRED."

                                                                          Page 2
<PAGE>

            (f) Communication of Offer. The offer to sell the Shares was
directly communicated to the Subscriber. At no time was the Subscriber presented
with or solicited by any leaflet, newspaper or magazine article, radio or
television advertisement, or any other form of general advertising or solicited
or invited to attend a promotional meeting otherwise than in connection and
concurrently with such communicated offer.

            (g) Certain Trading Activities. The Subscriber has not directly or
indirectly, nor has any person acting on behalf of or pursuant to any
understanding with the Subscriber, engaged in any trading in any securities of
the Company (including, without limitations, any Short Sales (defined below)
involving the Company's securities) during the 20 trading days immediately
preceding the Closing. For purposes of this Section, "Short Sales" include,
without limitation, all "short sales" as defined in Rule 3b-3 of the Securities
Exchange Act of 1934, as amended (the "1934 Act") and include all types of
direct and indirect stock pledges, forward sale contracts, options, puts, calls,
short sales, swaps and similar arrangements (including on a total return basis),
and sales and other transactions through non-U.S. broker dealers or foreign
regulated brokers having the effect of hedging the securities or investment made
under this Agreement. As of the date of this Agreement, the Subscriber has no
open short position in the Common Stock, and covenants that neither it nor any
person acting on its behalf or pursuant to any understanding with it will engage
in any Short Sales prior to the public disclosure of the material terms of this
transaction by the Company.

            (h) Correctness of Representations. The Subscriber represents that
the foregoing representations and warranties are true and correct as of the date
hereof and, unless the Subscriber otherwise notifies the Company prior to the
Closing Date (as hereinafter defined), shall be true and correct as of the
Closing Date. The foregoing representations and warranties shall survive the
Closing Date.

      2. Company Representations and Warranties. The Company represents and
warrants to and agrees with the Subscriber that:

            (a) Due Incorporation. The Company is a corporation duly organized,
validly existing and in good standing under the laws of the State of Delaware
and has the requisite corporate power to own its properties and to carry on its
business as now being conducted. The Company is duly qualified as a foreign
corporation to do business and is in good standing in each jurisdiction where
the nature of the business conducted or property owned by it makes such
qualification necessary, other than those jurisdictions in which the failure to
so qualify would not have a material adverse effect on the business, operations
or financial condition of the Company.

            (b) Outstanding Stock. All issued and outstanding shares of capital
stock of the Company have been duly authorized and validly issued and are fully
paid and non-assessable.

            (c) Authority; Enforceability. This Agreement has been duly
authorized, executed and delivered by the Company and is valid and binding
agreement enforceable in accordance with its terms, subject to bankruptcy,
insolvency, fraudulent transfer, reorganization, moratorium and similar laws of
general applicability relating to or affecting creditors' rights generally and
to general principles of equity; and the Company has full corporate power and
authority necessary to enter into this Agreement and to perform its obligations
hereunder.

                                                                          Page 3
<PAGE>

            (d) Shares Duly Authorized. The Shares when issued and delivered in
accordance with the terms of this Agreement, will be duly authorized, validly
issued, fully paid and non-assessable.

            (e) Stop Transfer. The Shares are restricted securities as of the
date of this Agreement. The Company will not issue any stop transfer order or
other order impeding the sale, resale or delivery of the Stock, except as may be
required by federal securities laws.

            (f) No General Solicitation. Neither the Company, nor any of its
affiliates, nor to its knowledge, any person acting on its or their behalf, has
engaged in any form of general solicitation or general advertising (within the
meaning of Regulation S or D under the Act) in connection with the offer or sale
of the Shares.

      3. Regulation S Offering. This Offering is being made pursuant to the
exemption from the registration provisions of the 1933 Act afforded by
Regulation S thereunder.

      4. Reissuance of Shares. The Company, or any of its affiliates, the legend
set forth in Section 1(e) above at such time as (a) the holder thereof is
permitted to and disposes of such Shares pursuant to Rule 144(d) and/or Rule
144(k) of the 1933 Act in the opinion of counsel reasonably satisfactory to the
Company, or (b) upon resale of the Shares pursuant to an effective registration
statement under the 1933 Act. The Company agrees to cooperate with the
Subscriber in connection with all resales pursuant to Rule 144(d) and Rule
144(k) of the 1933 Act and provide legal opinions necessary to allow such
resales provided the Company and its counsel receive requested written
representations from the Subscriber and selling broker, if any.

      5. "Piggy-Back" Registration Rights.

            (a) The Company agrees that when it registers any Common Stock under
the Securities Act by registration on Form SB-2 or other similar form for sale
for the account of one or more holders of Common Stock, the Company will
register the Shares in such registration statement. The Company will pay all
expenses incident to the registration of the Shares hereunder and the Company's
performance of or compliance with this Agreement.

            (b) The Seller will furnish to the Company in writing such
information and representation letters with respect to itself and the proposed
distribution by it as reasonably shall be necessary in order to assure
compliance with federal and state securities laws.

      6. Fees and Expenses. Each party shall pay the fees and expenses of its
advisers, counsel, accountants and other experts, if any, and all other expenses
incurred by such party incident to the negotiation, preparation, execution,
delivery and performance of this Agreement. The Company shall pay all stamp and
other taxes and duties levied in connection with the issuance of the Securities.

      7. Miscellaneous.

            (a) Notices. All notices, demands, requests, consents, approvals,
and other communications required or permitted hereunder shall be in writing
and, unless otherwise specified herein, shall be (i) personally served, (ii)
deposited in the mail, registered or certified, return receipt requested,
postage prepaid, (iii) delivered by reputable air courier service with charges
prepaid, or (iv) transmitted by hand delivery, telegram, or facsimile, addressed
as set forth below or to such other address as such party shall have specified
most recently by written notice. Any notice or other communication required or
permitted to be given hereunder shall be deemed effective (a) upon hand delivery
or delivery by facsimile, with accurate confirmation generated by the
transmitting facsimile machine, at the address or number designated below (if
delivered on a business day during normal business hours where such notice is to
be received), or the first business day following such delivery (if delivered
other than on a business day during normal business hours where such notice is
to be received) or (b) on the second business day following the date of mailing
by express courier service, fully prepaid, addressed to such address, or upon
actual receipt of such mailing, whichever shall first occur. The addresses for
such communications shall be: (i) if to the Company to Calypte Biomedical
Corporation, 5 Centerpointe Drive, Suite 400, Lake Oswego, Oregon 97035,
facsimile number: (917) 204-0284, and (ii) if to the Subscriber, to the name,
address and facsimile number set forth on the signature page hereto.

                                                                          Page 4
<PAGE>

            (b) Closing. The closing of the transactions contemplated by this
Agreement (the "Closing") shall take place on June 16, 2006 at 5:00 p.m.
(Pacific Standard Time) or such other location and time as may be determined by
the Company at the offices of Paula Winner Barnett, Esq., 17967 Boris Drive,
Encino, California, 91316. At the Closing, the Subscriber shall deliver to the
Company the Purchase Price in United States dollars and in immediately available
funds, by wire transfer to the following account:

      Pay to:                            FC - Silicon Valley Bank
                                         3003 Tasman Drive
                                         Santa Clara, CA 95054, USA
      Routing & Transit #:               \\FW:121140399
                                         --------------
      Swift Code:                        SVBKUS6S
      For Credit of:                     Calypte Biomedical Corporation
      Final Credit Account #:            FNC - 3300349200

            (c) Entire Agreement; Assignment. This Agreement represents the
entire agreement between the parties hereto with respect to the subject matter
hereof and may be amended only by a writing executed by both parties. No right
or obligation of either party shall be assigned by that party without the
written consent of the other party.

            (d) Execution. This Agreement may be executed in separate
counterparts, each of which shall be deemed an original and both of which shall
constitute one and the same document. This Agreement may be executed by
facsimile transmission.

            (e) Governing Law. This Agreement shall be governed by and construed
in accordance with the laws of the State of Oregon without regard to principles
of conflicts of laws. Any action brought by either party against the other
concerning the transactions contemplated by this Agreement shall be brought only
in the state courts of Oregon or in the federal courts located in the state of
Oregon. Both parties and the individuals executing this Agreement agree to
submit to the jurisdiction of such courts and waive trial by jury. The
prevailing party shall be entitled to recover from the other party its
reasonable attorney's fees and costs. In the event that any provision of this
Agreement or any other agreement delivered in connection herewith is invalid or
unenforceable under any applicable statute or rule of law, then such provision
shall be deemed inoperative to the extent that it may conflict therewith and
shall be deemed modified to conform with such statute or rule of law. Any such
provision which may prove invalid or unenforceable under any law shall not
affect the validity or enforceability of any other provision of any agreement.

                                                                          Page 5
<PAGE>

            (f) Specific Enforcement, Consent to Jurisdiction. The Company and
the Subscriber acknowledge and agree that irreparable damage would occur in the
event that any of the provisions of this Agreement were not performed in
accordance with their specific terms or were otherwise breached. It is
accordingly agreed that the parties shall be entitled to an injunction or
injunctions to prevent or cure breaches of the provisions of this Agreement and
to enforce specifically the terms and provisions hereof or thereof, this being
in addition to any other remedy to which any of them may be entitled by law or
equity. Subject to Section 7(e) hereof, each of the Company and the Subscriber
hereby waives, and agrees not to assert in any such suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of such court,
that the suit, action or proceeding is brought in an inconvenient forum or that
the venue of the suit, action or proceeding is improper. Nothing in this Section
shall affect or limit any right to serve process in any other manner permitted
by law.

                  [REMAINDER OF PAGE INTENTIONALLY BLANK]

                                                                          Page 6
<PAGE>

      IN WITNESS WHEREOF, the parties have hereby executed this Agreement as of
the day set forth in the acceptance set forth below.

                                        SUBSCRIBER NAME:
-----------------------------------
Number of Shares which Subscriber
Desires to Purchase

                                        By:
-----------------------------------        -------------------------------------
Dollar Amount of Subscription
Tendered by Subscriber

                                        ----------------------------------------
                                        (Street Address)

                                        ----------------------------------------
                                        (City and State)              (Zip Code)

                                        ----------------------------------------
                                        Telephone Number

                                   ACCEPTANCE

      The foregoing subscription is hereby accepted, subject to the terms and
conditions hereof, as of June __, 2006.

------------------------------------    CALYPTE BIOMEDICAL CORPORATION
Amount of Subscription Accepted

                                        By:
------------------------------------       -------------------------------------
Number of Shares                           Name:  Roger I. Gale
                                           Title:  Chief Executive Officer

                                                                          Page 7EMPLOYMENT AGREEMENT

      THIS EMPLOYMENT AGREEMENT (the "Agreement") is entered into as of the 28th
of June 2006, by Calypte Biomedical Corporation, a Delaware corporation
("Calypte") and Mr. Roger I. Gale (the "Employee"), Apartment 1806, No.1 West
India Quay, 24 Hertsmere Road, London, E14 4ED.

      Calypte desires to employ the Employee as President and Chief Executive
Officer of Calypte, and the Employee desires to be so employed, on the terms and
conditions set forth in this Agreement.

      ACCORDINGLY, on the basis of the representations, warranties, and
covenants contained in this Agreement, the parties agree as follows:

            ARTICLE 1 - EMPLOYMENT AND TERM

            1.1. Employment. Calypte shall employ the Employee as its President
and Chief Executive Officer, and the Employee accepts such employment, on the
terms and conditions set forth in the Agreement.

            1.2. Term. Unless the parties terminate or extend Employee's
employment in accordance with the terms of this Agreement, the term of
Employee's employment under this Agreement shall commence effective the 1st of
August 2006, and shall continue for a period of 24 months thereafter. Upon the
expiration of such 24-month period, the term of the Employee's employment under
this Agreement shall automatically renew for successive periods of 12 months
each, unless, at least 60 days before the expiration of such 24 month period or
any succeeding 12-month period, either party gives written notice to the other
party of its intention not to renew the Agreement. If such notice of non-renewal
is timely given, the term of the Employee's employment under this Agreement
shall expire at the end of such 24-month period or at the end of the current
12-month period, as the case may be. The term of Employee's employment under
this Agreement is referred to herein as the "Term."

            ARTICLE 2 - DUTIES OF THE EMPLOYEE

            2.1. Duties. During the Term, the Employee agrees to serve as
President and Chief Executive Officer of Calypte. Subject to the direction and
authorization of Calypte's board of directors (the "Board of Directors"), the
Employee shall direct and manage the affairs of Calypte and shall perform such
other functions and undertake such other responsibilities as are customarily
associated with his capacity as President and Chief Executive Officer. The
Employee shall devote his full business time, attention and skill to the
performance of such duties, services and responsibilities, and will use his best
efforts to promote the interests of Calypte. The Employee shall, at all times
during the Term, adhere to and obey any and all written internal rules and
regulations governing the conduct of Calypte's employees, as established or
modified from time to time; provided, however, that, in the event of any
conflict between the provisions of this Agreement and any such rules or
regulations, the provisions of this Agreement shall control.

<PAGE>

            2.2. Exclusive Services. During the Term, the Employee will not,
without the prior written approval of the Board of Directors, engage, directly
or indirectly, in any other business activity which would interfere with the
performance of his duties, services and responsibilities hereunder or which is
in violation of policies established from time to time by the Board of
Directors.

            2.3. Directorships. Notwithstanding the foregoing, the Employee
shall be permitted to continue holding non-employee directorships with AOA
Mechel and WaveCrest Group Enterprises and such other directorships as may be
agreed upon by the Board of Directors. All costs associated with holding these
directorships shall be borne by the Employee.

            ARTICLE 3 - COMPENSATION

            3.1. Base Salary. During the Term, Calypte shall pay to the Employee
a base salary at the annual rate of $350,000 per year, payable in equal
bi-weekly installments, less tax required to be withheld and other applicable
withholdings.

            3.2. Common Stock Award. Upon commencement of the Term, Calypte
shall award to the Employee 1,500,000 shares of its common stock, which shall be
fully vested upon the award, in accordance with the terms and conditions of
Calypte's 2004 Incentive Plan (the "Plan").

            3.3. Incentive Plan Award. Calypte shall award to the Employee
1,250,000 Restricted Stock Units or other similar incentive award (the "RSUs"),
which will vest quarterly in increments of 312,000 RSUs per quarter, except in
the last quarter wherein the increment shall be 314,000 RSUs, in accordance with
the terms and conditions of Calypte's 2004 Incentive Plan (the "Plan"). This
incentive award will be granted as soon as practicable, but in no event later
than 60 days after the date of this Agreement.

            3.4. Bonus. The Employee shall be entitled to receive an annual
bonus of up to 50% of his annual base salary upon satisfaction of performance
goals to be determined by the Board of Directors. The bonus may be paid in
either cash or equity or a combination of cash and equity. The Board of
Directors will set the performance goals within 60 days of execution of this
Agreement. The performance goals shall be measured and the bonus calculated as
of the end of each calendar year. For the calendar year ending December 31,
2006, the bonus will be based on the Employee's prorated salary for that
calendar year of $145,833.

            3.5. Employee Benefits. The Employee shall be entitled to
participate in or receive benefits under any employee benefit plans,
arrangements and perquisites, including, but not limited to, retirement plans,
supplemental retirement plans, pension plans, profit-sharing plans, health and
accident plans, medical coverage plans, disability plans, insurance programs,
and incentive compensation plans or any other employee benefit plan or
arrangement now available or in the future available to senior executives of
Calypte on the same basis as is available to other senior executives of Calypte.
Calypte will not, without the Employee's prior written consent, make any changes
in such plans, benefits or arrangements which would materially adversely affect
the Employee's rights or benefits thereunder, except to the extent such changes
are made applicable to all executive-level employees on a non-discriminatory
basis.

                                      -2-
<PAGE>

            3.6. Vacation. The Employee shall be entitled to 25 days paid
vacation each year. A maximum of 5 days may be carried forward in any one year.

            3.7. Reimbursement for Business Expenses. Calypte shall reimburse
the Employee for all reasonable and documented actual business expenses that the
Employee incurs from time to time in the performance of his duties under this
Agreement in accordance with the policies and practices that Calypte has adopted
or adopts hereafter. The class of air travel shall be business class or similar
for trips longer than 3 hours and business class or similar for all surface
travel.

            3.8. Personal Travel. The Company shall reimburse the Employee for
reasonable and documented actual expenses the Employee incurs from time to time
related to his and his spouse's personal travel up to a maximum of $15,000 per
year.

            3.9. Relocation Allowance. Calypte shall reimburse the Employee for
all reasonable and documented actual expenses, which shall be agreed in advance,
that the Employee incurs related to his and his spouse's relocation to Portland,
Oregon or other location as may be agreed to by the Employee and the Board of
Directors. This shall include packing and unpacking of household belongings,
international shipping and storage expenses, reasonable storage expenses of
household belongings in the United Kingdom, one way Business Class airfare from
London to Portland for the Employee and this spouse.

            3.10. Repatriation. The Company shall reimburse the Employee for all
reasonable and documented actual expenses, which shall be agreed to in advance,
that the Employee incurs related to his repatriation from Portland or other
location to the United Kingdom upon termination of this Agreement, unless a
subsequent employer agrees to reimburse the Employee for such expenses. The
Company shall reimburse the Employee for Business Class airfare from Portland to
the United Kingdom (or such other destination at no greater cost) for the
Employee and his spouse upon repatriation.

            3.11. Housing Allowance. During the term of this Agreement, Calypte
shall reimburse the Employee actual expenses up to $3,000 per month as a housing
allowance, payable in accordance with the policies established from time to time
by Calypte for its senior executive officers.

            3.12. Automobile Allowance. During the Term, Calypte shall reimburse
the Employee up to $800 per month for the costs and expenses incurred by the
Employee for the purchase or lease of an automobile, payable in accordance with
the policies established from time to time by Calypte for its senior executive
officers.

            3.13. Legal and Tax Advise Expenses. Calypte shall assist and
reimburse the Employee for all reasonable documented and actual expenses
incurred by the Employee to obtain the necessary documents for him to perform
his stated duties of this Agreement in Lake Oswego, Portland. Calypte shall
similarly reimburse the Employee up to $2,500 for the Employees reasonable
documented and actual expenses incurred to consult with a tax expert regarding
the Employee's income tax liabilities in connection with his compensation and
benefits under this Agreement.

                                      -3-
<PAGE>

            ARTICLE 4 - TERMINATION

            4.1. Termination for Cause. Termination for Cause shall mean
termination because of Employee's personal dishonesty, incompetence, failure to
adequately perform stated duties, willful misconduct, breach of fiduciary duty
involving personal profit, willful violation of any law, rule or regulation
(other than traffic violations or similar offenses), conviction of a felony or
other serious crime, or material breach of any provision of this Agreement. For
purposes of this Agreement, no act, or the failure to act, on the Employee's
part shall be "willful" unless done, or omitted to be done, not in good faith
and without reasonable belief that the action or omission was in the best
interest of Calypte. Notwithstanding the foregoing, the Employee shall not be
deemed to have been terminated for Cause unless and until there shall have been
delivered to him a notice of termination specifying the particulars thereof in
detail. The Employee shall not have the right to receive compensation or other
benefits for any period after termination for Cause which have not vested or
been earned as of the date of such termination. The Employee shall have the
right to receive compensation or other benefits which have already vested or
been earned as of the date of termination for Cause, unless payment of such
compensation or benefits is expressly prohibited by the terms of any plan,
program or agreement governing such compensation or benefits.

            4.2. Termination Upon An Other Event of Termination

                  (a) Upon the occurrence of an Other Event of Termination (as
herein defined) during the Term, the provisions of this Section 4.2 shall apply.
As used in this Agreement, an "Other Event of Termination" shall mean and
include any one or more of the following: (i) the termination by Calypte of the
Employee's employment hereunder for any reason other than a termination governed
by Sections 4.1, 4.3 or 4.4 hereof; (ii) the Employee's resignation upon any (A)
a material change in the Employee's function, duties, or responsibilities, which
change would cause the Employee's position to become one of lesser
responsibility, importance, or scope from the position and attributes thereof
described in Sections 1.1 and 2.1 hereof, unless consented to by the Employee,
(B) a relocation of the Employee's principal place of employment by more than
100 miles, unless consented to by the Employee, (C) a material reduction in the
aggregate benefits and perquisites to the Employee from those being provided as
of the effective date of this Agreement, unless such reduction is (I) consented
to by the Employee, (II) applies generally to executive-level employees of
Calypte, or (III) is a reduction in the amount of the Employee's bonus based on
the application of a formula or index to the financial performance of Calypte.
Upon the occurrence of any event described in clauses (A), (B), or (C), above,
the Employee shall have the right to elect to terminate his employment under
this Agreement by resignation upon not less than 30 days prior written notice
given within six months after the event giving rise to said right to elect.

                  (b) Upon the occurrence of an Other Event of Termination,
Calypte shall be obligated to pay the Employee, or, in the event of his
subsequent death, his beneficiary or beneficiaries, or his estate, as the case
may be, an amount equal to the Employee's base salary on the date of termination
for 12 months. Such amount shall be paid in 12 equal monthly installments
commencing on the 30th day after the Termination Date, or under such other
arrangements as shall be agreed with the Employee. Such amount shall be in
addition to any compensation or benefits earned by the Employee or to which the
Employee was entitled prior to the Termination Date. Such payments shall not be
reduced in the event the Employee obtains other employment following termination
of employment.

                                      -4-
<PAGE>

                  (c) Upon the occurrence of an Other Event of Termination,
Calypte will cause to be continued life, medical, dental and disability coverage
substantially identical to the coverage maintained by Calypte for the Employee
prior to his termination at no premium cost to the Employee, except to the
extent such coverage may be changed in its application to all executive-level
employees of Calypte if such coverage was generally available on the date of an
Other Event of Termination to executive-level employees of Calypte, or except to
the extent such coverage may be changed in its application to all
executive-level employees of Calypte if such coverage was generally available on
the date of an Other Event of Termination to executive-level employees of
Calypte. The benefits provided under this Section 4.3(c) shall continue until
the earlier of (a) six month following Employee's termination of employment with
Calypte, (b) the end of the then current Term, or (c) the date the Employee
becomes covered under any other group health plan not maintained by Calypte. In
the event Employee is required to make an election under Sections 601 through
607 of the Employee Retirement Income Security Act of 1974 (commonly known as
COBRA) to qualify for the benefits described in this Section 4.3(c), the
obligations of Calypte under this Section 4.3(c) shall be conditioned upon the
Employee's timely making such an election.

            4.3. Termination By the Employee or Death. If the Employee
terminates his employment with Calypte for any reason other than the reasons set
forth in Section 4.2 hereof or the Employee's employment is terminated as a
result of his death, Calypte shall pay to the Employee, or in the event of his
death, his beneficiary or beneficiaries or his estate, as the case may be, the
base salary earned but unpaid pursuant to Section 3.1 hereof through the
Termination Date and any earned but unused vacation pay due to the Employee at
the Termination Date. Any such payments due to the Employee, under this Section
4.3 shall be paid on the Termination Date, unless the termination of the
Employee's employment was due to his death, in which case, such payment shall be
made by no later than 30 days after the Termination Date. The Employee shall not
have the right to receive compensation or other benefits for any period after
the Termination Date which have not vested or been earned as of the Termination
Date. The Employee shall have the right to receive compensation or other
benefits which have already vested or been earned as of the Termination Date,
unless payment of such compensation or benefits is expressly prohibited by the
terms of any plan, program or agreement governing such compensation or benefits.

            4.4. Termination on Disability. If (i) the Employee is absent from
work for 90 calendar days in any 12-month period by reason of illness or
incapacity (whether physical or otherwise) or (ii) the Board of Directors
reasonably determines that the Employee is unable to perform his duties,
services and responsibilities hereunder by reason of illness or incapacity
(whether physical or otherwise) for a total of 90 calendar days in any 12-month
period during the Term ("Disability"), Calypte may terminate the Employee's
employment hereunder as of the Termination Date specified in a written notice
termination from Calypte to the Employee. If the Employee's employment is
terminated by Calypte pursuant to this Section 4.4, Calypte shall pay on the
Termination Date to the Employee the base salary earned but unpaid pursuant to
Section 3.1 hereof through the Termination Date and any earned but unused
vacation pay due to the Employee at the Termination Date. In addition, the
Employee shall be entitled to receive benefits based on Calypte's applicable
disability plans then in effect. The Employee shall not have the right to
receive compensation or other benefits for any period after the Termination Date
which have not vested or been earned as of the Termination Date. The Employee
shall have the right to receive compensation or other benefits which have
already vested or been earned as of the Termination Date, unless payment of such
compensation or benefits is expressly prohibited by the terms of any plan,
program or agreement governing such compensation or benefits.

                                      -5-
<PAGE>

            4.5. Termination of Calypte's Obligation. If, at any time within one
year following termination of employment, the Employee materially breaches any
of the Employee's obligations under Articles 5 or 6 of this Agreement, then, in
addition to any other remedy of Calypte, Calypte's obligation, if any, to make
payments under Section 4.1 shall cease as of the date such material breach
occurs. Moreover, the Employee acknowledges that a material breach of Articles 5
or 6 of this Agreement will cause irreparable harm to Calypte and, if the
Employee fails to abide by these obligations, Calypte will be entitled to seek
specific performance, including immediate issuance of a temporary restraining
order or preliminary injunction enforcing this Agreement, and to seek judgment
for damages caused by the Employee's breach, and to seek other remedies provided
by applicable law.

            4.6. Termination Date. Any termination of the Employee's employment
hereunder pursuant to this Article 4 shall be effected by written notice other
than a termination as a result of the Employee's death. Any written notice of
termination shall indicate the specific termination provision in this Agreement
relied upon and shall set forth in reasonable detail the facts and circumstances
claimed to provide a basis for termination of the Employee's employment under
the provisions so indicated. The effective date of any such termination (the
"Termination Date") shall be as follows:

                  (a) In the event of a termination due to the Employee's death,
the date of such death; and

                  (b) In the event of termination for any reason other than the
Employee's death, the date specified in the written notice of termination which
in no event shall be prior to the date of receipt of such notice.

            ARTICLE 5 - CONFIDENTIALITY AND NON-SOLICITATION

                                      -6-
<PAGE>

            5.1. Nondisclosure. The Employee acknowledges that in the course of
employment with Calypte, the Employee will have access to learn confidential
information concerning Calypte. Confidential information includes, but is not
limited to, information about either Calypte's affiliates, vendors, suppliers,
distributors and clients, the terms and conditions under which Calypte or its
affiliates deals with vendors, suppliers, distributors and clients, sales and
product information, manufacturing processes, product formulations, information
regarding applications and submissions (relating to existing and proposed
products) made to various regulatory bodies, new product plans, product
development efforts, marketing strategies, financial information and projections
and other commercial and product data, pricing information for products,
financing arrangements, research materials, manuals, computer programs, data,
marketing plans and tactics, technical information, processes and practices of
Calypte, all information contained in electronic or computer files, salary and
wage information, and any other information that is designated in writing by
Calypte or its affiliates as confidential or that the Employee knows or should
know is confidential; information provided by third parties that Calypte is
obligated to keep confidential; and all other proprietary information of
Calypte. The Employee acknowledges that all confidential information is and
shall continue to be the exclusive property of Calypte, whether or not prepared
in whole or in part by the Employee and whether or not disclosed to or entrusted
to the Employee in connection with employment by Calypte. The Employee agrees
not to disclose confidential information, directly or indirectly, under any
circumstances or by any means, to any third persons without the prior written
consent of Calypte. The Employee agrees that he will not copy, transmit,
reproduce, summarize, quote, or make any commercial or other use whatsoever of
confidential information, except as may be necessary to perform work done by
Employee for Calypte. The Employee agrees to exercise the highest degree of care
in safeguarding confidential information against loss, theft or other
inadvertent disclosure and agrees generally to take all steps necessary or
requested by Calypte to ensure maintenance of the confidentiality of the
confidential information. The Employee agrees in addition to the specific
covenants contained herein to comply with all of Calypte's policies and
procedures for the protection of confidential information.

            5.2. Exclusions. Section 5.1 shall not apply to the following
information: (a) information previously, now or hereafter voluntarily
disseminated by Calypte to the public or which otherwise becomes part of the
public domain through lawful means; (b) information known to the Employee prior
to the Employee's employment with Calypte; (c) information received by the
Employee from third parties not known by the Employee to be subject to a
confidentiality agreement with Calypte; or (d) information, including but not
limited to, information concerning banking, financial and/or economic
principles, concepts or ideas which is not solely and exclusively derived from
the business plans and activities of Calypte.

            5.3. Confidential Proprietary and Trade Secret Information of
Others. The Employee represents that he has disclosed to Calypte any agreement
to which the Employee is or has been a party regarding the confidential
information of others and the Employee understands that the Employee's
employment by Calypte will not require the Employee to breach any such
agreement. The Employee will not disclose such confidential information to
Calypte nor induce Calypte to use any trade secret proprietary information
received from another under an agreement or understanding prohibiting such use
or disclosure.

            5.4. Non-Solicitation of Employees. During the period of one year
after the Termination Date, the Employee shall not directly or indirectly
solicit for employment or for independent contractor work any employee of
Calypte, and shall not encourage any such employee to leave the employment of
Calypte.

                                      -7-
<PAGE>

            5.5. Non-Solicitation of Customers. During the period of one year
following the Termination Date, the Employee shall not directly or indirectly
(a) solicit for business any customers of Calypte, (b) encourage any such
customers to stop using the facilities or services of Calypte, or (c) encourage
any such customers to use the facilities or services of any competitor of
Calypte.

            5.6. No Unfair Competition. The Employee hereby acknowledges that
the sale or unauthorized use or disclosure of any of Calypte's Confidential
Material obtained by the Employee by any means whatsoever, at any time before,
during, or after the Term shall constitute unfair competition. The Employee
shall not engage in any unfair competition with Calypte either during the Term
or at any time thereafter.

            ARTICLE 6 - CALYPTE'S OWNERSHIP IN EMPLOYEE'S WORK

            6.1. Calypte's Ownership. The Employee agrees that all inventions,
discoveries, improvements, trade secrets, formulae, techniques, processes, and
know-how, whether or not patentable, and whether or not reduced to practice,
that are conceived or developed during the Employee's employment with Calypte,
either alone or jointly with others, if on Calypte's time, using Calypte's
facilities, relating to Calypte or to its current or prospective business, shall
be owned exclusively by Calypte, and the Employee hereby assigns to Calypte all
the Employee's right, title, and interest in all such intellectual property. The
Employee agrees that Calypte shall be the sole owner of all domestic and foreign
patents or other rights pertaining thereto, and further agrees to execute all
documents that Calypte reasonably determines to be necessary or convenient for
use in applying for, prosecuting, perfecting, or enforcing patents or other
intellectual property rights, including the execution of any assignments, patent
applications, or other documents that Calypte may reasonably request. This
provision is intended to apply only to the extent permitted by applicable law.

            6.2. Section 6.1 shall not apply to inventions that the Employee has
developed entirely on his own time without using Calypte's equipment, supplies,
facilities, trade secret information or Confidential Information, except that
Section 6.1 will apply to inventions that either (i) relate at the time of
conception or reduction to practice of the invention to Calypte's business, or
actual or demonstrably anticipated research or development of Calypte or (ii)
result from any work that the Employee performed for Calypte. The Employee will
advise Calypte promptly in writing of any inventions that the Employee believes
meet the foregoing criteria.

            6.3. Return of Calypte's Property and Materials. Upon termination of
employment with Calypte, the Employee shall deliver to Calypte all Calypte
property and materials that are in the Employee's possession or control,
including all of the information described as confidential information in
Section 6 of this Agreement and including all other information relating to any
inventions, discoveries, improvements, trade secrets, formulae, processes, or
know-how of Calypte.

            6.4. Ventures. If Employee, during employment with Calypte, is
engaged in or associated with the planning or implementation of any project,
program, or venture involving Calypte and any third parties, all rights in the
project, program, or venture shall belong to Calypte, and the Employee shall not
be entitled to any interest therein or to any commission, finder's fee, or other
compensation in connection therewith other than the salary to be paid to the
Employee as provided in this Agreement.

                                      -8-
<PAGE>

            ARTICLE 7 - ARBITRATION

      Any claim or controversy between the parties which the parties are unable
to resolve themselves, including any claim arising out of the Employee's
employment or the termination of that employment, and including any claim
arising out of, connected with, or related to the formation, interpretation,
performance or breach of this Agreement, and any claim or dispute as to whether
a claim is subject to arbitration, shall be submitted to and resolved
exclusively by expedited arbitration by a single arbitrator in accordance with
the following procedures:

            7.1. In the event of a claim or controversy subject to this
arbitration provision, the complaining party shall promptly send written notice
to the other party identifying the matter in dispute and the proposed remedy.
Following the giving of such notice, the parties shall meet and attempt in good
faith to resolve the matter. In the event the parties are unable to resolve the
matter within 21 days, the parties shall meet and attempt in good faith to
select a single arbitrator acceptable to both parties. If a single arbitrator is
not selected by mutual consent within 10 business days following the giving of
the written notice of dispute, an arbitrator shall be selected from a list of
nine persons each of whom shall be an attorney who is either engaged in the
active practice of law or a recognized arbitrator and who, in either event, is
experienced in serving as an arbitrator in disputes between employers and
employees, which list shall be provided by the main Portland, Oregon office of
the American Arbitration Association ("AAA") or of the Federal Mediation and
Conciliation Service. If, within three business days of the parties' receipt of
such list, the parties are unable to agree upon an arbitrator from the list,
then the parties shall each strike names alternatively from the list, with the
first to strike being determined by the flip of a coin. After each party has had
four strikes, the remaining name on the list shall be the arbitrator. If such
person is unable to serve for any reason, the parties shall repeat this process
until an arbitrator is selected.

            7.2. Unless the parties agree otherwise, within 120 days of the
selection of the arbitrator, a hearing shall be conducted before such arbitrator
at a time and a place in Portland, Oregon agreed upon by the parties. In the
event the parties are unable to agree upon the time or place of the arbitration,
the time and place within Portland, Oregon shall be designated by the arbitrator
after consultation with the parties. Within 30 days of the conclusion of the
arbitration hearing, the arbitrator shall issue an award, accompanied by a
written decision explaining the basis for the arbitrator's award.

            7.3. In any arbitration hereunder, Calypte shall pay all
administrative fees of the arbitration and all fees of the arbitrator. Each
party shall pay its own attorneys' fees, costs, and expenses, unless the
arbitrator orders otherwise. The prevailing party in such arbitration, as
determined by the arbitrator, and in any enforcement or other court proceedings,
shall be entitled, to the extent permitted by law, to reimbursement from the
other party for all of the prevailing party's costs (including but not limited
to the arbitrator's compensation), expenses, and attorneys' fees. The arbitrator
shall have no authority to add to or to modify this Agreement, shall apply all
applicable law, and shall have no lesser and no greater remedial authority than
would a court of law resolving the same claim or controversy. The arbitrator
shall, upon an appropriate motion, dismiss any claim without an evidentiary
hearing if the party bringing the motion establishes that it would be entitled
to summary judgement if the matter had been pursued in court litigation. The
parties shall be entitled to reasonable discovery subject to the discretion of
the arbitrator.

                                      -9-
<PAGE>

            7.4. The decision of the arbitrator shall be final, binding, and
non-appealable, except as otherwise permitted by law, and may be enforced as a
final judgment in any court of competent jurisdiction.

            7.5. This Agreement to resolve any disputes by arbitration shall
extend to claims against any parent, subsidiary, or affiliate of each party,
and, when acting within such capacity, any officer, director, shareholder,
employee or agent of each party, or of any of the above, and shall apply as well
to claims arising out of state and federal statutes and local ordinances as well
as to claims arising under the common law or under this Agreement. This
Agreement, however, shall not apply to claims for workers' compensation or
unemployment compensation benefits.

            7.6. Notwithstanding the foregoing, and unless otherwise agreed
between the parties, either party may, in an appropriate matter, apply to a
court for provisional relief, including a temporary restraining order or
preliminary injunction, on the ground that the arbitration award to which the
applicant may be entitled may be rendered ineffectual without provisional
relief.

            7.7. Any arbitration hereunder shall be conducted in accordance with
the employment rules and procedures of the AAA then in effect; provided,
however, that, in the event of any inconsistency between the rules and
procedures of the AAA and the terms of this Agreement, the terms of this
Agreement shall prevail.

            7.8. If any of the provisions of this Section 7 are determined to be
unlawful or otherwise unenforceable, in whole or in part, such determination
shall not affect the validity of the remainder of this Section 7, and this
Section 7 shall be reformed to the extent necessary to carry out its provisions
to the greatest extent possible and to insure that the resolution of all
conflicts between the parties, including those arising out of statutory claims,
shall be resolved by neutral, binding arbitration. If a court should find that
the provisions of this Section 7 are not absolutely binding, then the parties
intend any arbitration decision and award to be fully admissible in evidence in
any subsequent action, given great weight by any finder of fact, and treated as
determinative to the maximum extent permitted by law.

            ARTICLE 8 - MISCELLANEOUS

            8.1. Indemnification. In the event the Employee is made, or
threatened to be made, a party to any legal action or proceeding, whether civil
or criminal, by reason of the fact that the Employee is or was an officer of
Calypte, the Employee shall be indemnified by Calypte, and Calypte shall pay the
Employee's related expenses when and as incurred, all to the fullest extent
permitted by law but subject to all conditions and requirements of applicable
law.

                                      -10-
<PAGE>

            8.2. Cooperation in Defense of Calypte. If the Employee, during the
Term or thereafter, is served with any subpoena or other compulsory judicial or
administrative process calling for production of confidential information or if
the Employee is otherwise required by law or regulations to disclose
confidential information, the Employee will promptly, before making any such
production or disclosure, notify Calypte and provide it with such information as
Calypte may reasonably request to take such action as Calypte deems necessary to
protect its interests. The Employee agrees to cooperate reasonably with Calypte,
whether during the Term or thereafter, in the prosecution or defense of all
threatened claims or actual litigation in which Calypte is or may become a
party, whether now pending or hereafter brought, in which the Employee has
knowledge of relevant facts or issues. The Employee shall be promptly reimbursed
out-of-pocket expenses due to cooperating with the prosecution or defense of any
litigation for Calypte.

            8.3. Severable Provisions. The provisions of this Agreement are
separate and distinct, and if any provisions are determined to be unenforceable,
in whole or in part, the remaining provisions, and the enforceable parts of any
partially unenforceable provisions, shall nevertheless be enforceable.

            8.4. Successors and Assigns. This Agreement shall inure to the
benefit of and be binding upon Calypte, its successors and assigns, and upon the
Employee and his heirs, executors, administrators and legal representatives. The
Company shall have the right to assign its rights and obligations under this
Agreement to an entity which acquires substantially all of the assets of the
Company. The Employee may not delegate his duties hereunder.

            8.5. Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be deemed an original and all of which taken
together constitutes one and the same instrument and in making proof hereof it
shall not be necessary to produce or account for more than one such counterpart.

            8.6. Waiver. Neither party shall, by mere lapse of time, without
giving notice or taking other action hereunder, be deemed to have waived any
breach by the other party of any of the provisions of this Agreement. Further,
the waiver by either party of a particular breach of this Agreement by the other
shall neither be construed as, nor constitute a, continuing waiver of such
breach or of other breaches by the same or any other provision of this
Agreement.

            8.7. Governing Law. The validity, interpretation, performance and
enforcement of this Agreement shall be governed by the laws of the State of
Oregon (without regard to the choice of law provisions of Oregon), but only to
the extent no superseded by federal law.

            8.8. Headings. Section and subsection headings do not constitute
part of this Agreement. They are included solely for convenience and reference,
and they in no way define, limit, or describe the scope of this Agreement or the
intent of any of its provisions.

                                      -11-
<PAGE>

            8.9. Integration. This Agreement, including any documents expressly
incorporated into it by the terms of this Agreement, constitutes the entire
agreement between the parties and supersedes all prior oral and written
agreements, understandings, negotiations, and discussions relating to the
subject matter of this Agreement. With this Agreement the parties rescind any
previous employment agreements or arrangements between themselves. Any
supplement, modification, waiver, or termination of this Agreement is valid only
if it is set forth in a writing signed by both parties. The waiver of any
provision of this Agreement shall not constitute a waiver of any other
provisions and, unless otherwise stated, shall not constitute a continuing
waiver.

            8.10. Notice. Any notice or other communication required or
permitted under this Agreement shall be in writing and shall be deemed to have
been given (i) if personally delivered, when so delivered, (ii) if mailed, two
days after having been placed in the United States mail, registered or
certified, postage prepaid, addressed to the party to whom it is directed at the
address listed below or (iii) if given by facsimile, when the notice is
transmitted to the facsimile number specified below, and the appropriate
answerback or telephonic confirmation is received:

      If to Calypte:

      5 Centerpointe Drive, Suite 400
      Lake Oswego, OR  97035
      Attention:   Corporate Secretary
      Telephone: (971) 204-0282
      Facsimile:  (971) 204-0284

      If to the Employee:

      5 Centerpointe Drive, Suite 400
      Lake Oswego, OR  97035
      Telephone: (971) 204-0282
      Facsimile:  (971) 204-0284

In order for a party to change its address or other information for the purpose
of this section, the party must first provide notice of that change in the
manner required by this section.

      EACH PARTY ACKNOWLEDGES that it has had an opportunity to negotiate,
carefully consider, and receive advice on the terms of this Agreement before
signing it.

      IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed as of the date and year set forth below.

                                        Calypte Biomedical Corporation

                                        By: /s/ Julius R. Krevans
                                           -------------------------------------
                                        Name:   Julius R. Krevans
Date: June 21, 2006                     Title:  Director
     ----------------------------               Chair, Compensation Cmte.

                                        By: /s/ Roger I. Gale
                                           -------------------------------------
Date: 28 June 2006                      Name: Mr. Roger Gale
      ----------------------------

                                      -12-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}]]